10-Q: Heartflow Reports Strong Revenue Growth Amidst Rising Losses

Heartflow, Inc. announced a 41% revenue increase in Q3 2025, driven by higher case volumes, and significantly improved its cash position following its August 2025 IPO, despite continued net losses and a new DOJ investigation.

Summary

• Revenue for Q3 2025 increased 41% to $46.3 million, and for the nine months ended September 30, 2025, increased 40% to $126.9 million, compared to the same periods in 2024.
• Net loss for Q3 2025 was $(50.9) million, a significant increase from $(19.1) million in Q3 2024, primarily due to a $32.1 million charge from common stock warrant liability remeasurement and a $6.4 million loss on debt extinguishment.
• Net loss for the nine months ended September 30, 2025, was $(92.4) million, compared to $(63.5) million in the prior year.
• Gross margin improved slightly to 77% for Q3 2025 (from 76% in Q3 2024) and to 76% for the nine months ended September 30, 2025 (from 75% in 2024).
• Operating expenses increased, with Research and Development up 46% to $17.3 million in Q3 2025 and Selling, General and Administrative up 19% to $33.2 million.
• The company completed its Initial Public Offering (IPO) on August 11, 2025, raising approximately $332.3 million net of offering costs.
• All outstanding redeemable convertible preferred stock and 2025 Convertible Notes converted into common stock upon the IPO, resulting in a positive stockholders' equity of $254.6 million as of September 30, 2025, compared to a deficit of $(859.5) million at December 31, 2024.
• Cash and cash equivalents significantly increased to $291.2 million as of September 30, 2025, from $51.4 million at December 31, 2024.
• The 2024 Term Loan was fully repaid and terminated in August 2025, eliminating $136.4 million in debt.
• Heartflow revenue cases increased 48% to 51,805 in Q3 2025 and 45% for the nine months ended September 30, 2025, compared to the prior year periods.
• A Civil Investigative Demand (CID) was received in October 2025 from the U.S. Department of Justice regarding an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.

Sentiment

Score: 4

Explanation: While revenue growth and a successful IPO are positive, the significant increase in net loss, growing accumulated deficit, and the new DOJ investigation introduce substantial uncertainty and risk, outweighing the operational improvements for the period.

Positives

• Strong revenue growth of 41% in Q3 2025 to $46.3 million and 40% for the nine months ended September 30, 2025, to $126.9 million.
• Improved gross margin to 77% in Q3 2025 and 76% for the nine months ended September 30, 2025, reflecting increased revenue case volume and improved production team productivity.
• Successful Initial Public Offering (IPO) on August 11, 2025, generating $332.3 million in net proceeds.
• Significant increase in cash and cash equivalents to $291.2 million as of September 30, 2025, from $51.4 million at December 31, 2024.
• Conversion of all redeemable convertible preferred stock and 2025 Convertible Notes into common stock, leading to a positive stockholders' equity of $254.6 million from a prior deficit.
• Full repayment and termination of the 2024 Term Loan in August 2025, eliminating $136.4 million in debt obligations.
• Substantial increase in Heartflow revenue cases by 48% in Q3 2025 to 51,805 and 45% for the nine months ended September 30, 2025.
• Net cash used in operating activities decreased to $(43.4) million for the nine months ended September 30, 2025, from $(55.0) million in the prior year, indicating improved operational cash efficiency.

Negatives

• Significant net loss of $(50.9) million in Q3 2025, a 166% increase from Q3 2024, and $(92.4) million for the nine months ended September 30, 2025, a 46% increase from the prior year.
• Accumulated deficit increased to approximately $1.1 billion as of September 30, 2025.
• A substantial $(32.1) million charge in Q3 2025 and $(34.6) million for the nine months ended September 30, 2025, from the remeasurement of common stock warrant liability negatively impacted net loss.
• A $(6.4) million loss on extinguishment of debt was recognized in Q3 2025 due to the full repayment of the 2024 Term Loan.
• Average sales price was reduced due to a higher percentage of revenue cases generated from clinic and office-based accounts and an increase in utilization and volume rebates.
• The company expects to continue incurring losses for the foreseeable future.
• Dependence on Heartflow FFR CT Analysis, which represents 98% of total revenue, poses a concentration risk.
• Increased operating expenses, with Research and Development up 46% and Selling, General and Administrative up 19% in Q3 2025.

Risks

• Incurred significant net losses since inception and expects to incur additional substantial losses, may not achieve or sustain profitability.
• Revenue is almost entirely generated from Heartflow FFR CT Analysis (98% of total revenue as of September 30, 2025), making the company highly dependent on its success.
• Healthcare providers may be unwilling to change their standard practice regarding CAD evaluation, adversely affecting adoption.
• Third-party payors, including government payors, may not cover or provide adequate reimbursement for the Heartflow Platform, or existing payment amounts may be reduced (e.g., proposed 15% reduction in Medicare reimbursement rate for Heartflow FFR CT Analysis in 2026).
• Faces risks associated with a concentrated customer base; loss of one customer could result in disproportionate loss across accounts (top two largest customers represented ~8% of 2024 revenue).
• Significant competition in an environment of rapid technological change, with competitors potentially developing more effective, accurate, reliable, or cost-effective products.
• Commercialization of Heartflow Plaque Analysis is nascent, and sufficient market acceptance or utilization levels may not be achieved.
• Risks associated with the use and development of AI models, including operational challenges, legal liability, reputational concerns, and competitive risks.
• Heartflow Platform and its data/models could have bugs, defects, or errors, including human quality control errors, or fail to meet expectations, adversely affecting reputation and operating results.
• Failure to properly manage future growth could suffer the business.
• Business could be disrupted by catastrophic events (e.g., earthquakes, fires, power loss, pandemics, cyberattacks).
• Consolidation among healthcare providers could lead to pressure for price concessions or reduced purchases.
• Acquisitions of other companies, solutions, or technologies could divert management attention, result in dilution, and disrupt operations.
• Sales to customers outside the United States expose the company to risks inherent in international sales, including regulatory, economic, and political risks.
• Failure to comply with laws and regulations affecting the transmission, security, and privacy of personal information (including health information) could result in significant penalties.
• Dependence on information technology systems, and any failure of these systems could harm the business.
• Reliance on third-party cloud-based infrastructure (AWS) exposes the company to service interruptions or security compromises.
• Failure to offer high-quality customer support could harm the business and reputation.
• Research and development investments may not translate into new products, features, or improvements, or may not be used efficiently.
• Networks and those of third-party service providers may become the target of bad actors or security breaches.
• Extensive regulatory requirements to bring products to market, and failure to receive/maintain regulatory clearances or approvals or to comply with medical device regulatory requirements could adversely affect the business.
• Delays in the commencement or completion of future or ongoing clinical testing could increase costs and delay ability to market for additional indications.
• Interim, top-line, and preliminary data from clinical trials may change as more patient data become available.
• Product liability claims could result in costly litigation and significant liabilities.
• Heartflow Platform may be subject to recalls, which could be costly and harm reputation and business (132 MAUDE reports between 2017 and Oct 31, 2025, including 109 for false negative results).
• Off-label or other unlawful promotion of products could result in costly investigations and sanctions.
• Subject to numerous federal, state, and foreign healthcare fraud and abuse, compliance, transparency, and privacy laws and regulations; failure to comply or an investigation (e.g., DOJ CID) could have an adverse effect.
• Subject to U.S. and foreign anti-corruption and anti-money laundering laws.
• Subject to governmental export and import controls.
• Future litigation could be costly and time-consuming.
• Inability to obtain and maintain sufficient intellectual property rights, or if the scope of rights is not sufficiently broad, third parties could develop similar products.
• Inability to protect the disclosure and use of confidential information and trade secrets.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and patent protection could be reduced or eliminated for noncompliance.
• Changes in patent law, precedents, and policies could diminish the value of patents.
• Inability to adequately protect intellectual property rights throughout the world.
• Involvement in lawsuits to protect or enforce patents or other intellectual property.
• Terms of patents may not be sufficiently long to effectively protect products.
• Failure to obtain additional protection under Hatch-Waxman Amendments or similar foreign legislation.
• Open-source software licenses may impose unanticipated or unclear restrictions or expose the company to litigation.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• May require additional capital, which might not be available on favorable terms or at all, and may dilute common stock ownership.
• Operating results may fluctuate significantly, making future results difficult to predict.
• Subject to risks associated with currency fluctuations.
• Ability to use net operating losses and tax credits may be subject to limitations (Section 382).
• International operations subject to potentially adverse tax consequences.
• Effective tax rate may vary significantly.
• Taxing authorities may successfully assert that sales and use, value added, or similar taxes should have been collected.
• No dividends intended in the foreseeable future.
• Market price of common stock may be volatile.
• Reduced reporting requirements as an emerging growth company could make common stock less attractive.
• Incurs increased costs and subject to additional regulations as a public company.
• Inability to design, implement, and maintain effective internal control over financial reporting.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Estimates or judgments relating to critical accounting policies may prove incorrect.
• Principal stockholders and management own a significant percentage of stock and can exert significant control.
• Sales of substantial number of shares by existing stockholders could cause stock price to decline.
• Delaware forum provision could limit stockholders' ability to obtain favorable judicial forum.
• Broad discretion in the use of IPO net proceeds.
• Securities litigation is expensive and could divert management attention.
• Provisions in charter documents and Delaware law could discourage a takeover.

Future Outlook

The company expects to continue incurring losses for the foreseeable future as it scales its business, invests in research and development, increases sales and marketing efforts, and incurs costs associated with being a public company. It anticipates existing cash and expected revenue will be sufficient to fund operations for at least the next 12 months. Future growth is dependent on the adoption of the CCTA+Heartflow pathway, successful introduction of new products like Heartflow Plaque Analysis and the upcoming Heartflow PCI Planner (expected 2026), and automation of production processes. Gross margin is expected to increase long-term due to AI automation, despite short-term fluctuations from hiring and training. The company is cooperating with a U.S. Department of Justice investigation, the outcome of which is uncertain but could have a material impact on its business.

Management Comments

• "We believe that we are the most widely adopted AI-powered test for CAD."
• "We believe the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance workflows, will continue to support our growth and advance the CCTA + Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD."
• "We expect to incur losses for the foreseeable future."
• "Based on our current operating plan, we believe that the expected cash generated from revenue transactions with customers and its existing cash and cash equivalents will be sufficient to fund the Companys planned operating expenses and capital expenditure requirements for at least the next 12 months from the date these condensed consolidated financial statements were available to be issued."
• "We expect our gross margin will increase over the long term as we leverage the AI-based nature of our software platform to automate an increasing number of the manual components of our production teams process, thereby lowering the cost of revenue per analysis."

Industry Context

Heartflow operates in the competitive medical technology industry, leveraging AI and computational fluid dynamics for non-invasive coronary artery disease (CAD) detection. The company aims to establish the CCTA + Heartflow pathway as the standard, competing against traditional non-invasive tests and emerging AI-based platforms. The industry faces evolving regulatory frameworks for AI, healthcare policy changes (like the OBBBA potentially reducing Medicaid spending and ACA marketplace access), and consolidation among healthcare providers, which could impact pricing and adoption. The company's focus on automation and new product development (Plaque Analysis, PCI Planner) aligns with broader trends in digital health and AI integration in diagnostics.

Comparison to Industry Standards

• The company states it is "the most widely adopted AI-powered test for CAD," implying a leading position in this specific niche.
• Competitors in traditional non-invasive CAD tests include GE Healthcare, Siemens Healthineers AG, and Koninklijke Philips N.V.
• Competitors developing AI-based platforms leveraging CCTA include Cleerly, Inc., Elucid Bioimaging Inc., and Keya Medical Technology Co., Ltd.
• The company's Heartflow FFR CT Analysis has Class 1, Level A guidelines for CCTA and Class 2a, Level B guidelines for FFR CT Analysis for certain patients, indicating clinical validation and recognition within medical standards.
• The proposed 2026 OPPS rule by CMS could result in a reduction of up to 15% in Medicare reimbursement for the clinical APC including Heartflow FFR CT Analysis, which is a specific industry-wide change impacting reimbursement.

Management Changes

Corporate Governance

Legal Proceedings

• In October 2025, the company and certain employees received Civil Investigative Demands (CID) from the U.S. Department of Justice, Civil Division.
• The CID is in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
• The CID requests information, documents, and testimony focused on the company's financial and contractual arrangements with providers and its sales and marketing activities.
• The company is cooperating with the Investigation but is unable to express a view on its likely duration, ultimate outcome, or estimate the possibility or range of any possible financial impact.
• Depending on the outcome, there may be a material impact on the company's business, results of operations, financial condition, or cash flows.
• The company may pursue or be subject to other litigation arising in the ordinary course of business, including intellectual property, product liability, breach of contract, commercial, employment, and other similar claims.

Related Party Transactions

• In January and March 2025, the company issued 2025 Convertible Notes to various investors and certain employees (Requisite Holders), including related parties.
• On January 24, 2025, Hayfin (a lender) converted $23.0 million of principal under the 2024 Term Loan to 2025 Convertible Notes under the same terms as other purchasers.
• John C.M. Farquhar (President and Chief Executive Officer), Campbell D.K. Rogers, M.D. (Chief Medical Officer), and Julie A. Cullivan (Director) adopted Rule 10b5-1 trading arrangements on September 12, 2025.

Stakeholder Impact

• Shareholders: Significant dilution from IPO and conversion of preferred stock/convertible notes. Potential for stock price volatility due to market factors, operating results, and sales by existing stockholders after lock-up expiration. Risk of decline in investment value due to continued losses and new legal investigation. No dividends expected.
• Employees: Adoption of 2025 Performance Incentive Plan and 2025 Employee Stock Purchase Plan provides new equity compensation opportunities. However, competition for highly qualified technical personnel is intense. Insider trading arrangements by key executives and a director could be perceived negatively.
• Customers (Medical Providers): Increased revenue case volume indicates growing adoption of Heartflow Platform. However, potential reduction in Medicare reimbursement rates and evolving payor coverage policies could impact their willingness to adopt or continue using the platform. The DOJ investigation could affect trust and relationships.
• Payors (Government and Commercial): Continued scrutiny over reimbursement rates and policies, with a proposed 15% reduction in Medicare reimbursement for Heartflow FFR CT Analysis. The OBBBA may reduce Medicaid spending and ACA marketplace access, potentially impacting patient access to diagnostics.
• Creditors: The full repayment and termination of the 2024 Term Loan reduces the company's debt obligations, improving its credit profile.

Next Steps

• Broaden market education efforts for Heartflow Plaque Analysis as payor coverage increases.
• Launch Heartflow PCI Planner in 2026.
• Continue to automate manual components of the production process using AI.
• Conduct clinical studies for expanded indications for use and develop new product offerings and enhancements.
• Expand operations, including hiring personnel, to drive and support anticipated growth.
• Manage incremental costs associated with operating as a public company.
• Cooperate with the U.S. Department of Justice investigation.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, 2024-03, 2025-05, 2025-06).
• Address potential changes in Medicare reimbursement rates (e.g., proposed 15% reduction for 2026 OPPS rule).

Key Dates

Recommendation

While Heartflow demonstrated strong revenue growth and significantly improved its liquidity and balance sheet through a successful IPO and debt repayment, the substantial increase in net losses and the newly disclosed U.S. Department of Justice investigation introduce considerable uncertainty and risk. The potential for reduced Medicare reimbursement rates further clouds the near-term outlook. Investors should hold to monitor the outcome of the investigation, the impact of reimbursement changes, and the company's path to profitability, as these factors will heavily influence future performance.

Keywords

Heartflow, Medical Technology, Coronary Artery Disease, CAD, AI, Artificial Intelligence, FFR CT Analysis, Plaque Analysis, PCI Planner, IPO, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Cash Flow, Debt Repayment, Stock Warrants, DOJ Investigation, Healthcare Reimbursement, Regulatory Compliance, Intellectual Property, Biotech, Diagnostics